期刊文献+

脂质体介导的重组质粒pIRES-hBMP-2-hVEGF_(165)体外转染对hBMSCs成骨能力的影响 被引量:2

INFLUENCE OF LIPOSOME-MEDIATED RECOMBINANT PLASMID pIRES-hBMP-2-hVEGF_(165) ON OSTEOGENIC ACTIVITY OF hBMSCs IN VITRO
原文传递
导出
摘要 目的探讨重组质粒pIRES-hBMP-2-hVEGF165体外转染对hBMSCs成骨诱导分化的影响。方法构建hBMP-2和hVEGF165真核共表达载体。取健康成人自愿捐献的骨髓分离培养hBMSCs,采用阳离子脂质体将构建的质粒pIRES-hBMP-2-hVEGF165、pIRES-hBMP-2、pIRES-hVEGF165和空质粒载体(pIRES-neo)转染至hBMSCs,作为A、B、C、D组;另取相同数量的未转染细胞作为对照组(E组)。培养4周,采用RT-PCR检测hBMP-2、hVEGF165以及骨钙mRNA表达,Western blot检测细胞hBMP-2和hVEGF165表达,定量检测ALP活性,免疫组织化学方法检测ColⅠ表达。结果与E组比较,A组hBMSCs高表达hBMP-2、hVEGF165、ColⅠ及骨钙素,B组大量表达骨钙素及ColⅠ,C组高表达hVEGF165,而B组hVEGF165及C组hBMP-2和ColⅠ的表达与D、E组相似,呈阴性或仅有痕量表达。A、B、C、D及E组ALP活性分别为0.91±0.03、0.90±0.02、0.64±0.03、0.67±0.01、0.66±0.02,A、B组与E组比较差异有统计学意义(P<0.05),C、D、E组差异无统计学意义(P>0.05)。结论重组质粒通过阳离子脂质体能成功转染hBMSCs,外源性hBMP-2和hVEGF165基因在转染细胞中能持续表达,并能增强hBMSCs的成骨能力。 Objective To investigate the effects of the recombinant plasmid pIRES-hBMP-2-hVEGF165 on differentiation and maturation of hBMSCs in vitro. Methods The co-expressing vector of hBMP-2 and hVEGF165 was constructed. The BMSCs were isolated and cultured from health adult human denoted marrow. By the lipofection method, the reconstructed plasmids pIRES-hBMP-2-hVEGF165, pIRES-hBMP-2, pIRES-hVEGF165 and pIRES neo empty vector, were transfected to hBMSCs (groups A, B, C and D). The untransfected cells were harvested as control group (group E). After 4 weeks of culture, RT-PCR was employed to assay the hBMP-2, hVEGFj65 and osteocalcin mRNA expression in hBMSCs. The expressions of hBMP-2 and hVEGF165 of BMSCs were assayed by Western blot. The level of ALP activities of BMSCs was determined. Col Ⅰ was also determined by immunohistochemical staining. Results Compared to group E, the hBMSCs in group A secreted high level of hBMP-2, hVEGF165, Col Ⅰ and osteocalcin; osteocalcin and Col Ⅰ expressed at high level in group B, and hVEGF165 expressed at high level in group C. Otherwise, the expression of hVEGF165 in group B and the expressions of hBMP-2 and ColⅠ in group C resemble to that of groups D and E, no expression or few expression was observed. The activities of ALP in groups A, B, C, D and E were 0.91± 0.03, 0.90 ±0.02, 0.64 ±0.03, 0.67 ± 0.01 and 0.66 ± 0.02, respectively. The activity of ALP of groups A and B were significantly increased compared with that of group E (P 〈 0.05); there was no significant difference among groups C, D and E (P 〉 0.05). Conclusion The recombinant plasmid plRES-hBMP-2-hVEGF165 can be successfully transfected into BMSCs with cation liposome-mediated transfection method, the exogenous hBMP-2 and hVEGF165 genes can be expressed constitutively in the transfected BMSCs, and it can enhance the differentiation abilities of BMSCs.
出处 《中国修复重建外科杂志》 CAS CSCD 北大核心 2009年第9期1124-1128,共5页 Chinese Journal of Reparative and Reconstructive Surgery
基金 国家自然科学基金资助项目(30600653) 四川省应用基础研究计划资助项目(2006J13-128) 四川省卫生厅科研课题资助项目(060044)~~
关键词 HBMSCS 诱导分化hBMP-2 HVEGF165 基因治疗 hBMSCs Differentiation hBMP-2 hVEGF165 Gene therapy
  • 相关文献

参考文献24

  • 1Reddi AH. Bone and cartilage differentiation. Curr Opin Genet Dev, 1994, 4(5): 737-744.
  • 2Erlebacher A, Filvaroff EH, Gitelman SE, et al. Toward a molecular understanding of skeketal development. Cell, 1995, 80(3): 371-378.
  • 3lZorriol F, Shapiro F. Bone Development: Interaction of Molecular Components and Biophysical Forces. Clin Orthop Relat Res, 2005, (432): 14-33.
  • 4Urist MR, Lietze A, Mizutani H, et al. A bovine low molecular weight bone morphogenetic protein (BMP) fraction. Clin Orthop Relat Res, 1982, (162): 219-232.
  • 5Termaat MF, Blokhuis TJ, Bakker FC, etal. The role of bone morphogenetic proteins in bone healing. Osteo Trauma Care, 2003, 11: 122-125.
  • 6Kofron MD, Laurencin CT. Orthopaedic applications of gene therapy. Curr Gene Ther, 2005, 5(1): 37-61.
  • 7Furumatsu T, Shen ZN, Kawai A, et al. Vascular Endothelial Growth Factor: Principally acts as the main angiogenic factor in the early stage of human osteoblastogenesis. J Biochem, 2003, 133(5): 633-639.
  • 8Hidaka C, Ibarra C, Hannafin JA, et al. Formation of vascularized meniscal tissue by combining gene therapy with tissue engineering. Tissue Eng, 2002, 8(1): 93-105.
  • 9Nussenbaum B, Rutherford RB, Teknos TN, et al. Ex Vivo Gene Therapy for Skeletal Regeneration in Cranial Defects Compromised by Post- operative Radiotherapy. Hum Gene Ther, 2003, 14(11): 1107-1115.
  • 10Chang SC, Wei FC, Chuang H, et al. Ex viva gene therapy in autologous critical-size craniofacial bone regeneration. Plast Reconstr Surg, 2003, 112(7): 1841-1850.

同被引文献15

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部